Cancer Drug Parity Act of 2019

Bill: 116-hr-1730
Sponsor: full_name: Rep. Higgins, Brian [D-NY-26]
Introduced: 2019-03-13
Policy area: Health
Subjects: Cancer

Drug therapy

Health care costs and insurance

Health care coverage and access

Prescription drugs
Latest action: action_date: 2019-03-14
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2019-03-13
action_desc: Introduced in House
text: <p><b>Cancer Drug Parity Act of 2019</b></p> <p>This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.</p>To comply with this requirement, health plans may not,&nbsp;with respect to&nbsp;anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

tv_txt: I 116th CONGRESS 1st Session H. R. 1730 IN THE HOUSE OF REPRESENTATIVES March 13, 2019 Mr. Higgins of New York (for himself, Mr. Guthrie , Ms. Matsui , Mr. Bilirakis , Mr. Kilmer , Mr. Fitzpatrick , Mr. King of New York , Mr. Nadler , Mr. DeFazio , Mr. Hastings , Mr. Olson , Ms. Wasserman Schultz , Mr. Hurd of Texas , Mr. Bera , Mr. Cole , Mr. Khanna , Mr. McCaul , and Ms. Norton ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Public Health Service Act to require group and individual health insurance coverage and group health plans to provide for cost sharing for oral anticancer drugs on terms no less favorable than the cost sharing provided for anticancer medications administered by a health care provider.

1. Short title This Act may be cited as the Cancer Drug Parity Act of 2019 . 2. Parity in cost sharing for oral anticancer drugs (a) Requirement (1) In general Section 2719A of the Public Health Service Act ( 42 U.S.C. 300gg–19a ) is amended by adding at the end the following new subsection: (e) Parity in cost sharing for oral anticancer drugs (1) In general Subject to paragraph (2), a group health plan, and a health insurance issuer offering group or individual health insurance coverage, that provides benefits with respect to anticancer medications administered by a health care provider shall provide that any cost sharing for prescribed, patient-administered anticancer medications that are used to kill, slow, or prevent the growth of cancerous cells and that have been approved by the Food and Drug Administration is no less favorable than the cost sharing for anticancer medications that is intravenously administered or injected by a health care provider. (2) Limitation Paragraph (1) shall only apply to an anticancer medication that is prescribed based on a finding by the treating physician that the medication— (A) is medically necessary for the purpose of killing, slowing, or preventing the growth of cancerous cells; or (B) is clinically appropriate in terms of type, frequency, extent site, and duration. (3) Restriction on certain changes A group health plan or health insurance issuer may not, in order to comply with the requirement of paragraph (1), make changes to benefits or replace existing benefits with new benefits under the plan or health insurance coverage designed to have the effect of— (A) imposing an increase in out-of-pocket costs with respect to anticancer medications; (B) reclassifying benefits with respect to anticancer medications in a way that would increase such costs; or (C) applying more restrictive limitations on prescribed orally administered anticancer medications than on intravenously administered or injected anticancer medications. (4) Construction Nothing in this subsection shall be construed— (A) to require the use of orally administered anticancer medications as a replacement for other anticancer medications; (B) to prohibit a group health plan or health insurance issuer from requiring prior authorization or imposing other appropriate utilization controls in approving coverage for any chemotherapy; or (C) to supersede a State law that provides greater protections with respect to the coverage with respect to orally administered anticancer medications than is provided under this subsection. (5) Cost sharing defined In this subsection, the term cost sharing includes a deductible, coinsurance, copayment, and any maximum limitation on the application of such a deductible, coinsurance, copayment, and similar out-of-pocket expenses. . (2) Conforming amendment Section 2724(c) of the Public Health Service Act ( 42 U.S.C. 300gg–23(c) ) is amended by striking section 2704 and inserting sections 2719A, 2725, and 2726 . (b) Clarifying amendment regarding application to grandfathered plans Section 1251(a)(4)(A) of the Patient Protection and Affordable Care Act ( 42 U.S.C. 18011(a)(4)(A) ) is amended by adding at the end the following new clause: (v) Section 2719A(e) (relating to cost sharing for oral anticancer drugs). . (c) Effective date The amendments made by this section shall apply with respect to group health plans for plan years beginning on or after January 1, 2020, and with respect to health insurance coverage offered, sold, issued, renewed, in effect, or operated in the individual or group market on or after such date.